Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced <i>ROS1</i> -Positive Non−Small Cell Lung Cancer

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2025-12-02
DOI
https://doi.org/10.1001/jamaoncol.2025.5097
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer

Beung‐Chul Ahn, Ki Hyeong Lee, Koung Jin Suh, Young Ju Lee et al.
JAMA Oncology
Lung Cancer Treatments and Mutations
article

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer

Beung‐Chul Ahn, Ki Hyeong Lee, Koung Jin Suh, Young Ju Lee, Dong-Wan Kim, Tae Min Kim, Se Hyun Kim, Ji‐Youn Han, Yu Jung Kim
article en

Abstract

No abstract available for this paper.
JAMA OncologyVol. 12(1)
Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), National Cancer Center (US), Chungbuk National University Hospital (KR)
Openalex Percentile: Top 45%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.